


A

Immune populations	N° cells/mm <sup>2</sup>		
	PRE-VACCIMEL	POST-VACCIMEL	POST-NIVOLUMAB
CD8 PT	147 ± 8	378 ± 11	706 ± 10
CD8 IT	1 ± 0	48 ± 8	106 ± 5
CD11c PT	42 ± 3	198 ± 6	207 ± 8
CD11c IT	19 ± 2	114 ± 3	205 ± 9
CD68 PT	96 ± 7	274 ± 9	150 ± 3
CD68 IT	104 ± 4	244 ± 5	137 ± 8

PT: peri-tumoral, IT: intra-tumoral

B



**Supplementary Figure 1. Immune infiltrate analysis of Patient#5 ITM biopsies.**

Comparative analysis of tumor-infiltrating immune populations was performed by immunohistochemistry on ITM biopsies obtained before and after VACCIMEL immunization, and following nivolumab treatment, as described under Methods. (A) Table with quantification of CD8, CD11c and CD68 positive cells, distinguishing zones with peritumoral (PT) and intratumoral (IT) infiltrate. (B) Bars show mean cells/mm<sup>2</sup> ±SD; bars with different letters are statistically different (Tukey's multiple comparisons test, p < 0.05)